Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with...

Area of Science:

• Hepatology
• Clinical Trials
• Pharmacology

Background:

• Decompensated cirrhosis significantly reduces patient survival, highlighting the need for effective treatments beyond liver transplantation.
• Granulocyte colony-stimulating factor (G-CSF) has shown promise in improving survival for acute-on-chronic liver failure.
• Erythropoietin has demonstrated hepatic regeneration capabilities in animal models.

Purpose of the Study:

• To investigate the efficacy of co-administering G-CSF and darbepoetin α in improving outcomes for patients with advanced decompensated cirrhosis.
• To evaluate the impact of this combination therapy on patient survival and disease severity markers.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 55 patients with decompensated cirrhosis.
• Patients received either subcutaneous G-CSF and darbepoetin α (GDP group, n=29) or placebo (control group, n=26) for 4 weeks, alongside standard medical therapy.
• The primary endpoint was 12-month survival, with secondary endpoints including liver severity scores and complication rates.

Main Results:

• The GDP group exhibited significantly higher 12-month survival rates (68.6%) compared to the control group (26.9%; P = .003).
• Combination therapy led to greater reductions in Child-Turcotte Pugh and Model for End Stage Liver Disease scores.
• The incidence of septic shock was substantially lower in the GDP group (6.9%) versus controls (38.5%; P = .005), with no major adverse events reported.

Conclusions:

• Co-administration of G-CSF and darbepoetin α offers a significant survival benefit for patients with decompensated cirrhosis.
• This combination therapy effectively reduces liver disease severity and lowers the risk of developing septic shock.
• The findings support the use of G-CSF and darbepoetin α as a potential therapeutic strategy for advanced cirrhosis.